The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Shares of GSK PLC GSK inched up 0.33% to £13.59 Tuesday, on what proved to be an all-around positive trading session for the ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

GSK PLC GSK shares shed 2.82% to £12.94 Tuesday, on what proved to be an all-around rough trading session for the stock ...

During Lacalle's meeting with British Prime Minister Boris Johnson, the launch of a sovereign bond linked to sustainability goals was discussed Pharmaceutical giant GlaxoSmithKline (GSK ...

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...